Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41467-018-03337-2
Title: A systematic approach to the development of a safe live attenuated Zika vaccine
Authors: Kwek, S.S
Watanabe, S 
Chan, K.R 
Ong, E.Z 
Tan, H.C 
Ng, W.C 
Nguyen, M.T.X 
Gan, E.S 
Zhang, S.L 
Chan, K.W.K 
Tan, J.H 
Sessions, O.M 
Manuel, M
Pompon, J 
Chua, C
Hazirah, S
Tryggvason, K 
Vasudevan, S.G 
Ooi, E.E 
Keywords: interferon regulatory factor 3
live vaccine
Zika virus vaccine
live vaccine
virus vaccine
cell
immunity
rodent
strategic approach
vaccine
vertical transmission
yellow fever
Zika virus disease
adult
animal cell
animal experiment
animal model
animal tissue
Article
B lymphocyte
controlled study
dendritic cell
drug efficacy
drug mechanism
drug safety
embryo
female
fetus
gene activation
genetic variability
genomic instability
human
human cell
in vitro propagation
infection risk
innate immunity
male
mouse
mouse model
next generation sequencing
nonhuman
single nucleotide polymorphism
T lymphocyte
umbilical vein endothelial cell
vaccine immunogenicity
Vero cell line
vertical transmission
virus culture
virus mutation
virus plaque
virus transmission
whole genome sequencing
wild type
Zika fever
Zika virus
Aedes
animal
evaluation study
genetics
growth, development and aging
immunological technique
immunology
virology
Zika fever
Flavivirus
Human immunodeficiency virus 1
Zika virus
Aedes
Animals
Dendritic Cells
Humans
Immunologic Techniques
Mice
Vaccines, Attenuated
Viral Vaccines
Zika Virus
Zika Virus Infection
Issue Date: 2018
Publisher: Nature Publishing Group
Citation: Kwek, S.S, Watanabe, S, Chan, K.R, Ong, E.Z, Tan, H.C, Ng, W.C, Nguyen, M.T.X, Gan, E.S, Zhang, S.L, Chan, K.W.K, Tan, J.H, Sessions, O.M, Manuel, M, Pompon, J, Chua, C, Hazirah, S, Tryggvason, K, Vasudevan, S.G, Ooi, E.E (2018). A systematic approach to the development of a safe live attenuated Zika vaccine. Nature Communications 9 (1) : 1031. ScholarBank@NUS Repository. https://doi.org/10.1038/s41467-018-03337-2
Abstract: Zika virus (ZIKV) is a flavivirus that can cause congenital disease and requires development of an effective long-term preventative strategy. A replicative ZIKV vaccine with properties similar to the yellow fever 17D (YF17D) live-attenuated vaccine (LAV) would be advantageous, as a single dose of YF17D produces lifelong immunity. However, a replicative ZIKV vaccine must also be safe from causing persistent organ infections. Here we report an approach to ZIKV LAV development. We identify a ZIKV variant that produces small plaques due to interferon (IFN)-restricted viral propagation and displays attenuated infection of endothelial cells. We show that these properties collectively reduce the risk of organ infections and vertical transmission in a mouse model but remain sufficiently immunogenic to prevent wild-type ZIKV infection. Our findings suggest a strategy for the development of a safe but efficacious ZIKV LAV. © 2018 The Author(s).
Source Title: Nature Communications
URI: https://scholarbank.nus.edu.sg/handle/10635/174234
ISSN: 2041-1723
DOI: 10.1038/s41467-018-03337-2
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41467-018-03337-2.pdf1.71 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

16
checked on Oct 22, 2020

Page view(s)

9
checked on Oct 22, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.